Alnylam Pharmaceuticals
ALNY
199 hedge funds and large institutions have $4.22B invested in Alnylam Pharmaceuticals in 2017 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 63 increasing their positions, 72 reducing their positions, and 36 closing their positions.
41% more capital invested
Capital invested by funds: $2.99B → $4.22B (+$1.22B)
2.49% more ownership
Funds ownership: 93.16% → 95.64% (+2.5%)
6% more call options, than puts
Call options by funds: $45.9M | Put options by funds: $43.4M
0% more funds holding in top 10
Funds holding in top 10: 8 → 8 (0)
6% less funds holding
Funds holding: 211 → 199 (-12)
13% less repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 72
19% less first-time investments, than exits
New positions opened: 29 | Existing positions closed: 36
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$219M |
| 2 |
PA
Perceptive Advisors
New York
|
+$45.5M |
| 3 |
RFS
Rockefeller Financial Services
New York
|
+$22.9M |
| 4 |
Goldman Sachs
New York
|
+$21.7M |
| 5 |
RI
RTW Investments
New York
|
+$14M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Legal & General Group
London,
United Kingdom
|
-$10.3M |
| 2 |
Millennium Management
New York
|
-$10.1M |
| 3 |
AG
Artal Group
Luxembourg
|
-$9.24M |
| 4 |
State Street
Boston,
Massachusetts
|
-$9.05M |
| 5 |
CWM
CIBC World Markets
New York
|
-$7.86M |
ALNY Hedge Fund Activity: Q1 2017 in Review
199 of the 4,034 institutional investors tracked by Wall St. Rank reported a position in Alnylam Pharmaceuticals (ALNY) for Q1 2017, worth a combined $4.22B — up 41% from $2.99B a quarter earlier.
Sellers outnumbered buyers: 36 funds closed out of ALNY and 29 opened new positions — a net loss of 7 holders — while 72 trimmed existing stakes and 63 added.
The largest buyer was BlackRock, adding an estimated $219M. The largest seller was Legal & General Group, cutting an estimated $10.3M.
- 199 institutional investors held Alnylam Pharmaceuticals (ALNY) as of Q1 2017, down from 211 in Q4 2016.
- Funds reported $4.22B of Alnylam Pharmaceuticals stock for Q1 2017, up 41% quarter-over-quarter.
- 29 funds opened new Alnylam Pharmaceuticals positions in Q1 2017 and 36 closed out, a net change of -7 holders.
- The largest Alnylam Pharmaceuticals buyer in Q1 2017 was BlackRock, an estimated $219M added.
- The largest Alnylam Pharmaceuticals seller in Q1 2017 was Legal & General Group, an estimated $10.3M sold.
Based on aggregated 13F filings for Q1 2017.